CLAIMS

What Is Claimed Is:

1. A topical composition comprising 25%w/w to 50%w/w hydrogen peroxide and 1%w/w to 5%w/w 2-propanol.

2. The topical composition of claim 1, wherein the composition comprises hydrogen peroxide in an amount of 50%w/w, 45%w/w, 40%w/w, 32.5%w/w, 25%w/w, or in a range between any two of these amounts.

3. The topical composition of claim 1, wherein the 2-propanol comprises up to 1.5%w/w, up to 2%w/w, up to 2.5%w/w, up to 3%w/w, up to 3.5%w/w, up to 4%w/w, or up to 4.5%w/w of the composition.

4. The topical composition of claim 1 further comprising a stabilizer.

5. The topical composition of claim 4, wherein the stabilizer comprises stannate, sodium pyrophosphate, organophosphonate, nitrate, phosphoric acid, colloidal silicate, or a combination thereof.

6. The topical composition of claim 1 further comprising a gelling agent.

7. The topical composition of claim 6, wherein the gelling agent is selected from high molecular weight cross linked copolymers of acrylic acid and a hydrophobic comonomer or a copolymer, PVP (polyvinyl pyrrolidone), Poloxamer, Bentonite, hyaluronic acids, cross-linked hyaluronic acids, silicates, or a combination thereof.

8. The topical composition of claim 1, wherein the composition has a surface tension of about 42 mN•m-1 to about 55 mN•m-1 at 37 ºC.

9. The topical composition of claim 1, wherein the 2-propanol is in an amount sufficient to decrease a surface tension of the composition to a level that effectively increases the penetration of the composition into crevices, invaginations and/or surface irregularities of a skin lesion.

10. The topical composition of claim 1, wherein the 2-propanol is in an amount sufficient to decrease surface tension while minimizing spread of the composition onto non-targeted skin when applied to a targeted lesion.

11. The topical composition of claim 1, wherein the composition is stable for at least two years at 5ºC, at least one year at 30ºC, at least 6 months at 40ºC, or a combination thereof.

12. The topical composition of claim 1, wherein the topical composition comprises 45%w/w stabilized cosmetic-grade hydrogen peroxide and 5%w/w 2-propanol, and wherein the topical composition has a surface tension of 42 mN•m-1 to 55 mN•m-1 at 37 ºC.

13. The topical composition of claim 1, wherein the topical composition comprises 40%w/w stabilized cosmetic-grade hydrogen peroxide and 5%w/w 2-propanol, and wherein the topical composition has a surface tension of 42 mN•m-1 to 55 mN•m-1 at 37 ºC.

14. The topical composition of claim 1, wherein the topical composition comprises 32.5%w/w stabilized cosmetic-grade hydrogen peroxide and 5%w/w 2-propanol, and wherein the topical composition has a surface tension of 42 mN•m-1 to 55 mN•m-1 at 37 ºC.

15. The topical composition of claim 1, wherein the topical composition comprises 25%w/w stabilized cosmetic-grade hydrogen peroxide and 5%w/w 2-propanol, and wherein the topical composition has a surface tension of 42 mN•m-1 to 50 mN•m-1 at 37 ºC.

16. Use of a topical composition comprising 25%w/w to 50% w/w hydrogen peroxide and 0.1%w/w to 5%w/w 2-propanol in the manufacture of a topical medicament.

17. The use of claim 16, wherein the composition comprises hydrogen peroxide in an amount of 50% w/w, 45% w/w, 40% w/w, 32.5% w/w, 25% w/w, or in a range between any two of these amounts.

18. The use of claim 16, wherein the topical medicament is for the treatment of a skin condition selected from the group consisting of warts, seborrheic keratosis, acrochordons, recalcitrant warts, recurrent warts, treatment naïve warts, common warts, palmoplantar warts, flat warts, epidermodysplasia verruciformis related warts, anogenital warts, condyloma accuminatum, cervical intraepithelial neoplasia (CIN), chicken pox, Herpes zoster, shingles, molluscum contagiosum, orf, callus, cutaneous horns, corns, fibroepithelial polyps, prurigo nodularis, actinic keratoses, squamous cell carcinoma, squamous cell carcinoma in situ, keratoacanthoma, basal cell

carcinoma, cutaneous lymphomas, benign lymphocytic infiltrates, hyperplasias of the skin, clear cell acanthoma, large cell acanthoma, epidermolytic acanthoma, porokeratosis, hyperkeratosis, keratosis pilaris, lichenoid keratosis, acanthosis, acanthosis nigricans, confluent papillomatosis, reticulated papillomatosis, nevi, acne, cysts, trichofolliculoma, fibrofolliculoma, perifollicular fibroma, trichodiscoma, nevus sebaceous, chondroid syringoma, trichoepithelioma, trichoblastoma, desmoplastic trichoepithelioma, pilomatricoma, pilomatrical carcinoma, tricholemmoma, trichelemmal carcinoma, tumor of the follicular infundibulum, tricoadenoma, proliferating pilar tumor, sebaceous hyperplasia, sebaceous adenoma, sebaceous epithelioma, sebaceous carcinoma, syringoma, poroma, hidradenoma, apocrine hidradenoma, spiradenoma, cylindroma, eccrine nevus, papillary adenoma, papillary adenocarcinoma, ephilides, café-au-lait macules, Becker's melanosis, lentigines, solar lentigines, lentigo simplex, mucosal melanocytic lesions, Mongolian spots, Nevus of Ota, blue nevus, common acquired melanocytic nevi, moles, congenital nevi, nevus spilus, recurrent nevi; vascular and perivascular neoplasms, hemangiomas, cherry angiomas, hobnail hemangiomas, tufted angiomas, hemangioendotheliomas, angiolymphoid hyperplasia with eosinophilia (ALHE), glomangiomas, hemangiopericytomas; neuromas, Schwannomas, neurofibromas, nerve sheath tumor, nerve sheath myxoma, neurothekeoma, granular cell tumor; fibroepithelial polyps, fibromas, fibrous papules, angiofibromas, pearly penile papules, periungual fibromas, dermatofibromas, fibrokeratomas, sclerotic or pleomorphic fibromas, connective tissue nevi, cutaneous scars, hyperplasias, keloids, rosacea, cutaneous fungal, dermatophyte infections, mold infections, onychomycosis, hyperpigmentation, rhytides, psoriasis, malignant melanoma, dermatosis papulosis nigra, inverted follicular keratosis, acrokeratosis verruciformis, stucco keratosis, and a combination thereof.

19. The use of claim 18, wherein the skin condition is selected from the group consisting of warts, common warts, recalcitrant warts, treatment naïve warts, molluscum contagiosum, acrochordons, seborrheic keratosis, condyloma acuminate, or a combination thereof.

20. The use of claim 18 further including debriding a treatment site of the subject.

21. The use of claim 20, wherein debriding the treatment site may occur before, after or concurrent with administration of the composition.

22. The use of claim 18, wherein the medicament is to be administered once daily, twice daily, weekly, twice weekly, bi-weekly, every other day, monthly, every two months, or every three months.

23. The use of claim 18, wherein the medicament is to be administered at least about 1 day, at least about 2 days, at least about 3 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least 1 month, at least two months, at least three months, at least 4 months, at least 5 months, or at least 6 months after the initial visit to the healthcare professional.

24. The use of claim 16, wherein the medicament is a solution or a gel.

25. The use of claim 16, wherein the medicament is to be administered by contacting a treatment site with an applicator selected from the group consisting of a sponge, a swab, a foam tipped stick, a cotton ball, a brush, a woven or non-woven fabric, roller, gauze, a glove, a pen-type applicator, a flocked doe-foot applicator, or a combination thereof.

26. The use of claim 18, wherein the medicament is to be administered by contacting a treatment site with a tip of an applicator, wherein the applicator comprises:

a frangible ampoule having the composition disposed therein,

an applicator body having the frangible ampoule arranged therein;

an applicator hub in fluid communication with the applicator body;

the tip arranged at a proximal end of the applicator hub; and

a filter arranged between the frangible ampoule and the tip.

27. An applicator configured to store and dispense the topical composition of claim 1, the applicator comprising:

a frangible ampoule having the agent disposed therein;

an applicator body having the frangible ampoule arranged therein;

an applicator hub in fluid communication with the applicator body;

a tip arranged at a proximal end of the applicator hub; and

a filter arranged between the frangible ampoule and the tip.

28. The applicator of claim 27 wherein the applicator body further comprises an additional ingredient of the topical composition disposed therein, whereby the agent is

released from the frangible ampoule responsive to the frangible ampoule being ruptured and is mixed with the additional ingredient in the applicator body prior to administration of the topical composition.

29. The applicator of claim 27, wherein the topical composition is released from the frangible ampoule responsive to the frangible ampoule being ruptured and flows through the applicator body, the filter, and out of the applicator through the tip.

30. The applicator of claim 27, further comprising a pressure area arranged on an outer surface of the applicator body to indicate a portion of the applicator body to apply pressure to rupture the frangible ampoule.